title: Reactive oxygen species responsive nanoprodrug to treat intracranial glioblastoma.
abstract: Chemotherapy for intracranial gliomas is hampered by limited delivery of therapeutic agents through the blood brain barrier (BBB). An optimal therapeutic agent for brain tumors would selectively cross the BBB, accumulates in the tumor tissue and be activated from an innocuous prodrug within the tumor. Here we show brain tumor-targeted delivery and therapeutic efficacy of a nanometer-sized prodrug (nanoprodrug) of camptothecin (CPT) to treat experimental glioblastoma multiforme (GBM). The CPT nanoprodrug was prepared using spontaneous nanoemulsification of a biodegradable, antioxidant CPT prodrug and α-tocopherol. The oxidized nanoprodrug was activated more efficiently than nonoxidized nanoprodrug, suggesting enhanced therapeutic efficacy in the oxidative tumor microenvironment. The in vitro imaging of U-87 MG glioma cells revealed an efficient intracellular uptake of the nanoprodrug via direct cell membrane penetration rather than via endocytosis. The in vivo study in mice demonstrated that the CPT nanoprodrug passed through the BBB and specifically accumulated in brain tumor tissue, but not in healthy brain tissue and other organs. The accumulation preferably occurred at the periphery of the tumor where cancer cells are most actively proliferating, suggesting optimal therapeutic efficacy of the nanoprodrug. The nanoprodrug was effective in treating subcutaneous and intracranial tumors. The nanoprodrug inhibited subcutaneous tumor growth more than 80% compared with control. The median survival time of mice implanted with an intracranial tumor increased from 40.5 days for control to 72.5 days for CPT nanoprodrug. This nanoprodrug approach is a versatile method for developing therapeutic nanoparticles enabling tumor-specific targeting and treatment. The nontoxic, tumor-specific targeting properties of the nanoprodrug system make it a safe, low cost, and versatile nanocarrier for pharmaceuticals, imaging agents, and diagnostic agents.
authors.affiliation: Department of Neurosurgery, Cedars-Sinai Medical Center, 8631 West Third Street, Suite 800 East, Los Angeles, California 90048, United States.
authors.forename: Bong-Seop
authors.initials: BS
authors.lastname: Lee
authors.forename: Takayuki
authors.initials: T
authors.lastname: Amano
authors.forename: Hong Qiang
authors.initials: HQ
authors.lastname: Wang
authors.forename: Joe L
authors.initials: JL
authors.lastname: Pantoja
authors.forename: Chi Woo
authors.initials: CW
authors.lastname: Yoon
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Hanson
authors.forename: Rina
authors.initials: R
authors.lastname: Amatya
authors.forename: Allen
authors.initials: A
authors.lastname: Yen
authors.forename: Keith L
authors.initials: KL
authors.lastname: Black
authors.forename: John S
authors.initials: JS
authors.lastname: Yu
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D002166:Camptothecin / Q000008:administration & dosage* / Q000737:chemistry; D045744:Cell Line, Tumor; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D053769:Nanocapsules / Q000008:administration & dosage* / Q000737:chemistry / Q000648:ultrastructure; D011355:Prodrugs / Q000008:administration & dosage*; D017382:Reactive Oxygen Species / Q000378:metabolism*; D016896:Treatment Outcome; D024502:alpha-Tocopherol / Q000008:administration & dosage
chemical_list: D000975:Antioxidants; D053769:Nanocapsules; D011355:Prodrugs; D017382:Reactive Oxygen Species; D024502:alpha-Tocopherol; D002166:Camptothecin